While only 7.5 to 11.3% of enrolled HCC had concurrent CTNNB1 and TP53 mutations and 10.2 to 20.2% of TP53 mutant HCC harbored CTNNB1 mutations, half (46 to 53%) of CTNNB1 mutant HCC carried TP53 mutations (SI Appendix, Table S2) (15, 18, –20), suggesting the critical role of TP53 mutations in mutant CTNNB1-associated liver cancer, at least for HCC patients in China. Here, TP53 is linked to liver cancer.